BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Öberg K, Knigge U, Kwekkeboom D, Perren A. Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii124-vii130. [PMID: 22997445 DOI: 10.1093/annonc/mds295] [Cited by in Crossref: 269] [Cited by in F6Publishing: 257] [Article Influence: 33.6] [Reference Citation Analysis]
Number Citing Articles
1 Strosberg J, Joish VN, Giacalone S, Perez-Olle R, Fish-Steagall A, Kapoor K, Dharba S, Lapuerta P, Benson AB. TELEPRO: Patient-Reported Carcinoid Syndrome Symptom Improvement Following Initiation of Telotristat Ethyl in the Real World. Oncologist 2019;24:1446-52. [PMID: 31189618 DOI: 10.1634/theoncologist.2018-0921] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 4.5] [Reference Citation Analysis]
2 Calin ML, Sadiq A, Arevalo G, Fuentes R, Flanders VL, Gupta N, Nasri B, Singh K. The First Case Report of Robotic Multivisceral Resection for Synchronous Liver Metastasis from Pancreatic Neuroendocrine Tumor: A Case Report and Literature Review. J Laparoendosc Adv Surg Tech A 2016;26:816-24. [PMID: 27454160 DOI: 10.1089/lap.2016.0342] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
3 Errasti Alustiza J, Espín Basany E, Reina Duarte A. Rare tumors of the rectum. Narrative review. Cir Esp 2014;92:579-88. [PMID: 24629769 DOI: 10.1016/j.ciresp.2013.06.019] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Carter CA, Schmitz B, Peterson PG, Quinn M, Degesys A, Jenkins J, Oronsky B, Scicinski J, Caroen S, Reid TR, Cabrales P, Brzezniak C. Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol 2016;9:164-70. [PMID: 27065848 DOI: 10.1159/000444633] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.4] [Reference Citation Analysis]
5 Grillo F, Valle L, Ferone D, Albertelli M, Brisigotti MP, Cittadini G, Vanoli A, Fiocca R, Mastracci L. KI-67 heterogeneity in well differentiated gastro-entero-pancreatic neuroendocrine tumors: when is biopsy reliable for grade assessment? Endocrine 2017;57:494-502. [PMID: 28726181 DOI: 10.1007/s12020-017-1364-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
6 Devata S, Kim EJ. Neoadjuvant chemotherapy with capecitabine and temozolomide for unresectable pancreatic neuroendocrine tumor. Case Rep Oncol 2012;5:622-6. [PMID: 23275776 DOI: 10.1159/000345369] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
7 Ma J, Dercle L, Lichtenstein P, Wang D, Chen A, Zhu J, Piessevaux H, Zhao J, Schwartz LH, Lu L, Zhao B. Automated Identification of Optimal Portal Venous Phase Timing with Convolutional Neural Networks. Acad Radiol 2020;27:e10-8. [PMID: 31151901 DOI: 10.1016/j.acra.2019.02.024] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
8 Sallinen V, Le Large TY, Galeev S, Kovalenko Z, Tieftrunk E, Araujo R, Ceyhan GO, Gaujoux S. Surveillance strategy for small asymptomatic non-functional pancreatic neuroendocrine tumors - a systematic review and meta-analysis. HPB (Oxford). 2017;19:310-320. [PMID: 28254159 DOI: 10.1016/j.hpb.2016.12.010] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 10.8] [Reference Citation Analysis]
9 Basu S, Ostwal V. The case for combined chemotherapy-peptide receptor radionuclide therapy (chemo-PRRT) strategy in metastatic neuroendocrine tumor: predicting and looking at the possible case scenarios. Eur J Nucl Med Mol Imaging 2016;43:2453-5. [PMID: 27542673 DOI: 10.1007/s00259-016-3497-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
10 Shen C, Yin Y, Chen H, Tang S, Yin X, Zhou Z, Zhang B, Chen Z. Neuroendocrine tumors of colon and rectum: validation of clinical and prognostic values of the World Health Organization 2010 grading classifications and European Neuroendocrine Tumor Society staging systems. Oncotarget. 2017;8:22123-22134. [PMID: 27902460 DOI: 10.18632/oncotarget.13641] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 2.8] [Reference Citation Analysis]
11 Davis A, Clarke S, Ayesa S, Chan DL. Marked improvement in hyperammonaemic encephalopathy from multimodal treatment of metastatic neuroendocrine tumour. BMJ Case Rep 2021;14:e241191. [PMID: 34193447 DOI: 10.1136/bcr-2020-241191] [Reference Citation Analysis]
12 Gallo M, Malandrino P, Fanciulli G, Rota F, Faggiano A, Colao A; On behalf of NIKE Group. Everolimus as first line therapy for pancreatic neuroendocrine tumours: current knowledge and future perspectives. J Cancer Res Clin Oncol 2017;143:1209-24. [DOI: 10.1007/s00432-017-2407-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
13 Alonso-Gordoa T, Capdevila J, Grande E. GEP-NETs update: Biotherapy for neuroendocrine tumours. Eur J Endocrinol. 2015;172:R31-R46. [PMID: 25430657 DOI: 10.1530/eje-14-0354] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
14 Ribeiro MJM, Alonso T, Gajate P, Molina J, Barquin A, Perna C, Grande E. Huge recurrent gastric neuroendocrine tumor: a second-line chemotherapeutic dilemma. Autops Case Rep 2018;8:e2018005. [PMID: 29515980 DOI: 10.4322/acr.2018.005] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
15 Melosky B. Low Grade Neuroendocrine Tumors of the Lung. Front Oncol 2017;7:119. [PMID: 28660170 DOI: 10.3389/fonc.2017.00119] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
16 Ruszniewski P, Valle JW, Lombard-Bohas C, Cuthbertson DJ, Perros P, Holubec L, Delle Fave G, Smith D, Niccoli P, Maisonobe P, Atlan P, Caplin ME; SYMNET study group. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study. Dig Liver Dis. 2016;48:552-558. [PMID: 26917486 DOI: 10.1016/j.dld.2015.12.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 5.2] [Reference Citation Analysis]
17 Singh S, Asa SL, Dey C, Kennecke H, Laidley D, Law C, Asmis T, Chan D, Ezzat S, Goodwin R. Diagnosis and management of gastrointestinal neuroendocrine tumors: An evidence-based Canadian consensus. Cancer Treat Rev. 2016;47:32-45. [PMID: 27236421 DOI: 10.1016/j.ctrv.2016.05.003] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 7.8] [Reference Citation Analysis]
18 Cella D, Beaumont JL, Hudgens S, Marteau F, Feuilly M, Houchard A, Lapuerta P, Ramage J, Pavel M, Hörsch D, Kulke MH. Relationship Between Symptoms and Health-related Quality-of-life Benefits in Patients With Carcinoid Syndrome: Post Hoc Analyses From TELESTAR. Clin Ther 2018;40:2006-2020.e2. [PMID: 30477789 DOI: 10.1016/j.clinthera.2018.10.008] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
19 Petersenn S, Koch CA. Neuroendocrine neoplasms – still a challenge despite major advances in clinical care with the development of specialized guidelines. Rev Endocr Metab Disord 2017;18:373-8. [DOI: 10.1007/s11154-018-9442-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
20 Fazio N, Martini J, Croitoru AE, Schenker M, Li S, Rosbrook B, Fernandez K, Tomasek J, Thiis-evensen E, Kulke M, Raymond E. Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors. Future Oncology 2019;15:1997-2007. [DOI: 10.2217/fon-2018-0934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
21 Rehfeld JF, Broedbaek K, Goetze JP, Knigge U, Hilsted LM. True Chromogranin A concentrations in plasma from patients with small intestinal neuroendocrine tumours. Scandinavian Journal of Gastroenterology 2020;55:565-73. [DOI: 10.1080/00365521.2020.1759141] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
22 Chan D, Moody L, Segelov E, Metz D, Strosberg J, Pavlakis N, Singh S. Follow-Up for Resected Gastroenteropancreatic Neuroendocrine Tumours: A Practice Survey of the Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) and the North American Neuroendocrine Tumor Society (NANETS). Neuroendocrinology 2018;107:32-41. [DOI: 10.1159/000488394] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
23 Zundler S, Strobel D, Manger B, Neurath MF, Wildner D. Pancreatic Panniculitis and Polyarthritis. Curr Rheumatol Rep 2017;19. [DOI: 10.1007/s11926-017-0690-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
24 Grillo F, Albertelli M, Annunziata F, Boschetti M, Caff A, Pigozzi S, Ferone D, Mastracci L. Twenty years of gastroenteropancreatic neuroendocrine tumors: is reclassification worthwhile and feasible? Endocrine 2016;53:58-62. [PMID: 26362059 DOI: 10.1007/s12020-015-0734-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
25 Basu S, Ranade R, Ostwal V, Shrikhande SV. PET-Based Molecular Imaging in Designing Personalized Management Strategy in Gastroenteropancreatic Neuroendocrine Tumors. PET Clinics 2016;11:233-41. [DOI: 10.1016/j.cpet.2016.02.004] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
26 Mansi R, Fani M. Design and development of the theranostic pair 177 Lu-OPS201/68 Ga-OPS202 for targeting somatostatin receptor expressing tumors. J Labelled Comp Radiopharm 2019;62:635-45. [PMID: 31112618 DOI: 10.1002/jlcr.3755] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
27 Pozas J, San Román M, Alonso-Gordoa T, Pozas M, Caracuel L, Carrato A, Molina-Cerrillo J. Targeting Angiogenesis in Pancreatic Neuroendocrine Tumors: Resistance Mechanisms. Int J Mol Sci 2019;20:E4949. [PMID: 31597249 DOI: 10.3390/ijms20194949] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
28 Paul D, Ostwal V, Bose S, Basu S, Gupta S. Personalized treatment approach to gastroenteropancreatic neuroendocrine tumors: a medical oncologist’s perspective. European Journal of Gastroenterology & Hepatology 2016;28:985-90. [DOI: 10.1097/meg.0000000000000674] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 1.6] [Reference Citation Analysis]
29 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterology Research and Practice 2018;2018:1-12. [DOI: 10.1155/2018/9647247] [Reference Citation Analysis]
30 Zhou JY, Rodríguez Blanco M, Sánchez Cabús S, Szafranska J, Nieto EP. Unclassifiable pancreatic tumour. A case report. Gastroenterol Hepatol 2021:S0210-5705(21)00087-X. [PMID: 33746027 DOI: 10.1016/j.gastrohep.2021.02.008] [Reference Citation Analysis]
31 Lee MS, O'Neil BH. Summary of emerging personalized medicine in neuroendocrine tumors: are we on track? J Gastrointest Oncol 2016;7:804-18. [PMID: 27747094 DOI: 10.21037/jgo.2016.08.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.4] [Reference Citation Analysis]
32 Thang SP, Lung MS, Kong G, Hofman MS, Callahan J, Michael M, Hicks RJ. Peptide receptor radionuclide therapy (PRRT) in European Neuroendocrine Tumour Society (ENETS) grade 3 (G3) neuroendocrine neoplasia (NEN) - a single-institution retrospective analysis. Eur J Nucl Med Mol Imaging 2018;45:262-77. [DOI: 10.1007/s00259-017-3821-2] [Cited by in Crossref: 46] [Cited by in F6Publishing: 38] [Article Influence: 11.5] [Reference Citation Analysis]
33 Regazzo D, Barbot M, Scaroni C, Albiger N, Occhi G. The pathogenic role of the GIP/GIPR axis in human endocrine tumors: emerging clinical mechanisms beyond diabetes. Rev Endocr Metab Disord 2020;21:165-83. [PMID: 31933128 DOI: 10.1007/s11154-019-09536-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
34 Narayanan S, Kunz PL. Role of Somatostatin Analogues in the Treatment of Neuroendocrine Tumors. Hematol Oncol Clin North Am 2016;30:163-77. [PMID: 26614375 DOI: 10.1016/j.hoc.2015.09.008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
35 Longcroft-Wheaton G, Bhandari P. Endoscopic resection of submucosal tumors. Expert Rev Gastroenterol Hepatol 2015;9:659-69. [PMID: 25634074 DOI: 10.1586/17474124.2015.1003366] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
36 Cavalcanti MS, Gönen M, Klimstra DS. The ENETS/WHO grading system for neuroendocrine neoplasms of the gastroenteropancreatic system: a review of the current state, limitations and proposals for modifications. Int J Endocr Oncol 2016;3:203-19. [PMID: 30338051 DOI: 10.2217/ije-2016-0006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
37 Heetfeld M, Chougnet CN, Olsen IH, Rinke A, Borbath I, Crespo G, Barriuso J, Pavel M, O'Toole D, Walter T; other Knowledge Network members. Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms. Endocr Relat Cancer. 2015;22:657-664. [PMID: 26113608 DOI: 10.1530/erc-15-0119] [Cited by in Crossref: 183] [Cited by in F6Publishing: 76] [Article Influence: 30.5] [Reference Citation Analysis]
38 Wang Y, Jin K, Tan H, Zhang P, Yang Q, Wang W, Li J, Shao C, Xue L, Feng S, Chen M, Yu X, Chen J. Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer Chemother Pharmacol 2017;80:507-16. [DOI: 10.1007/s00280-017-3367-9] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
39 Ryan P, McBride A, Ray D, Pulgar S, Ramirez RA, Elquza E, Favaro JP, Dranitsaris G. Lanreotide vs octreotide LAR for patients with advanced gastroenteropancreatic neuroendocrine tumors: An observational time and motion analysis.J Oncol Pharm Pract. 2019;25:1425-1433. [PMID: 30924737 DOI: 10.1177/1078155219839458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
40 Cokmert S, Demir L, Akder Sari A, Kucukzeybek Y, Can A, Akyol M, Bayoglu IV, Dirican A, Erten C, Tarhan MO. Synchronous appearance of a high-grade neuroendocrine carcinoma of the ampulla vater and sigmoid colon adenocarcinoma. Case Rep Oncol Med 2013;2013:930359. [PMID: 24368955 DOI: 10.1155/2013/930359] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
41 Blesl A, Krones E, Pollheimer MJ, Haybaeck J, Wiesspeiner U, Lipp RW, Kump P. Downgrading of a G3 Neuroendocrine Tumor to a G2 Tumor: Can First-Line Cytotoxic Chemotherapy Change the Tumor Biology? Case Rep Oncol 2017;10:1121-6. [PMID: 29430237 DOI: 10.1159/000484473] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
42 Özaslan E, Demir S, Karaca H, Güven K. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors. Eur J Gastroenterol Hepatol 2016;28:836-41. [PMID: 26945127 DOI: 10.1097/MEG.0000000000000619] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
43 Armbruster M, Sourbron S, Haug A, Zech CJ, Ingrisch M, Auernhammer CJ, Nikolaou K, Paprottka PM, Rist C, Reiser MF. Evaluation of neuroendocrine liver metastases: a comparison of dynamic contrast-enhanced magnetic resonance imaging and positron emission tomography/computed tomography. Invest Radiol. 2014;49:7-14. [PMID: 24002080 DOI: 10.1097/rli.0b013e3182a4eb4a] [Cited by in Crossref: 20] [Cited by in F6Publishing: 7] [Article Influence: 2.9] [Reference Citation Analysis]
44 Dasari A, Joish VN, Perez-Olle R, Dharba S, Balaji K, Halperin DM. Direct costs of carcinoid syndrome diarrhea among adults in the United States. World J Gastroenterol 2019; 25(47): 6857-6865 [PMID: 31885426 DOI: 10.3748/wjg.v25.i47.6857] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
45 Rodrigues Â, Castro-Poças F, Pedroto I. Neuroendocrine Rectal Tumors: Main Features and Management. GE Port J Gastroenterol 2015;22:213-20. [PMID: 28868410 DOI: 10.1016/j.jpge.2015.04.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
46 Grande E. Sequential treatment in disseminated well- and intermediate-differentiated pancreatic neuroendocrine tumors: Common sense or low rationale? World J Clin Oncol 2016; 7(2): 149-154 [PMID: 27081637 DOI: 10.5306/wjco.v7.i2.149] [Reference Citation Analysis]
47 Lappano R, Maggiolini M. Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts. Drugs 2017;77:951-65. [PMID: 28401445 DOI: 10.1007/s40265-017-0738-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 3.5] [Reference Citation Analysis]
48 Bezzi C, Mapelli P, Presotto L, Neri I, Scifo P, Savi A, Bettinardi V, Partelli S, Gianolli L, Falconi M, Picchio M. Radiomics in pancreatic neuroendocrine tumors: methodological issues and clinical significance. Eur J Nucl Med Mol Imaging 2021. [PMID: 33835220 DOI: 10.1007/s00259-021-05338-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
49 Thornblade LW, Warner SG, Melstrom L, Ituarte PHG, Chang S, Li D, Fong Y, Singh G. Does surgery provide a survival advantage in non-disseminated poorly differentiated gastroenteropancreatic neuroendocrine neoplasms? Surgery 2021;169:1417-23. [PMID: 33637345 DOI: 10.1016/j.surg.2021.01.026] [Reference Citation Analysis]
50 Baum RP, Kluge AW, Kulkarni H, Schorr-Neufing U, Niepsch K, Bitterlich N, van Echteld CJ. [(177)Lu-DOTA](0)-D-Phe(1)-Tyr(3)-Octreotide ((177)Lu-DOTATOC) For Peptide Receptor Radiotherapy in Patients with Advanced Neuroendocrine Tumours: A Phase-II Study. Theranostics 2016;6:501-10. [PMID: 26941843 DOI: 10.7150/thno.13702] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 11.4] [Reference Citation Analysis]
51 Mühlbacher AC, Juhnke C. Patient Preferences Concerning Alternative Treatments for Neuroendocrine Tumors: Results of the "PIANO-Study". Int J Technol Assess Health Care 2019;35:243-51. [PMID: 31044688 DOI: 10.1017/S0266462319000217] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
52 Krabbe JG, Monaghan PJ, Russell J, de Rijke YB. Analytical evaluation of a second generation assay for chromogranin A; a dual-site study. Clinical Chemistry and Laboratory Medicine (CCLM) 2016;54. [DOI: 10.1515/cclm-2015-0782] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
53 Han X, Yang J, Luo J, Chen P, Zhang Z, Alu A, Xiao Y, Ma X. Application of CT-Based Radiomics in Discriminating Pancreatic Cystadenomas From Pancreatic Neuroendocrine Tumors Using Machine Learning Methods. Front Oncol 2021;11:606677. [PMID: 34367940 DOI: 10.3389/fonc.2021.606677] [Reference Citation Analysis]
54 Kondo NI, Ikeda Y. Practical management and treatment of pancreatic neuroendocrine tumors. Gland Surg. 2014;3:276-283. [PMID: 25493259 DOI: 10.3978/j.issn.2227-684x.2013.12.05] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
55 Yalcin S, Bayram F, Erdamar S, Kucuk O, Oruc N, Coker A. Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up. Arch Med Sci 2017;13:271-82. [PMID: 28261279 DOI: 10.5114/aoms.2017.65449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
56 Tarquini M, Ambrosio MR, Albertelli M, de Souza PB, Gafà R, Gagliardi I, Carnevale A, Franceschetti P, Zatelli MC. A tool to predict survival in stage IV entero-pancreatic NEN. J Endocrinol Invest 2021;44:1185-92. [PMID: 32892316 DOI: 10.1007/s40618-020-01404-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
57 Barbieri F, Albertelli M, Grillo F, Mohamed A, Saveanu A, Barlier A, Ferone D, Florio T. Neuroendocrine tumors: insights into innovative therapeutic options and rational development of targeted therapies. Drug Discovery Today 2014;19:458-68. [DOI: 10.1016/j.drudis.2013.10.015] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 3.1] [Reference Citation Analysis]
58 Krug S, Boch M, Daniel H, Nimphius W, Müller D, Michl P, Rinke A, Gress TM. Streptozocin-Based Chemotherapy in Patients with Advanced Neuroendocrine Neoplasms--Predictive and Prognostic Markers for Treatment Stratification. PLoS One 2015;10:e0143822. [PMID: 26630134 DOI: 10.1371/journal.pone.0143822] [Cited by in Crossref: 40] [Cited by in F6Publishing: 33] [Article Influence: 6.7] [Reference Citation Analysis]
59 Inzani F, Petrone G, Fadda G, Rindi G. Cyto-histology in NET: what is necessary today and what is the future? Rev Endocr Metab Disord 2017;18:381-91. [PMID: 28871510 DOI: 10.1007/s11154-017-9428-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
60 Tagai N, Goi T, Morikawa M, Kurebayashi H, Kato S, Fujimoto D, Koneri K, Murakami M, Hirono Y, Noriki S, Katayama K. Favorable response of colonic mixed adenoneuroendocrine carcinoma to streptozocin monotherapy. Int Cancer Conf J 2017;6:175-9. [PMID: 31149497 DOI: 10.1007/s13691-017-0301-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Basu S, Ranade R, Thapa P. Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour: developing a personalized model. Nucl Med Commun 2015;36:766-74. [PMID: 25920048 DOI: 10.1097/MNM.0000000000000321] [Cited by in Crossref: 12] [Cited by in F6Publishing: 4] [Article Influence: 2.4] [Reference Citation Analysis]
62 Sadaria MR, Hruban RH, Edil BH. Advancements in pancreatic neuroendocrine tumors. Expert Rev Gastroenterol Hepatol. 2013;7:477-490. [PMID: 23899286 DOI: 10.1586/17474124.2013.811058] [Cited by in Crossref: 11] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
63 Garcia-Carbonero R, Garcia-Figueiras R, Carmona-Bayonas A, Sevilla I, Teule A, Quindos M, Grande E, Capdevila J, Aller J, Arbizu J, Jimenez-Fonseca P; Spanish Cooperative Group of Neuroendocrine Tumors (GETNE). Imaging approaches to assess the therapeutic response of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): current perspectives and future trends of an exciting field in development. Cancer Metastasis Rev 2015;34:823-42. [PMID: 26433592 DOI: 10.1007/s10555-015-9598-5] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 5.0] [Reference Citation Analysis]
64 Terlević R, Perić Balja M, Tomas D, Skenderi F, Krušlin B, Vranic S, Demirović A. Somatostatin receptor SSTR2A and SSTR5 expression in neuroendocrine breast cancer. Ann Diagn Pathol 2019;38:62-6. [PMID: 30476894 DOI: 10.1016/j.anndiagpath.2018.11.002] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
65 Young K, Iyer R, Morganstein D, Chau I, Cunningham D, Starling N. Pancreatic neuroendocrine tumors: a review. Future Oncol 2015;11:853-64. [PMID: 25757686 DOI: 10.2217/fon.14.285] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
66 Haugvik SP, Janson ET, Österlund P, Langer SW, Falk RS, Labori KJ, Vestermark LW, Grønbæk H, Gladhaug IP, Sorbye H. Surgical Treatment as a Principle for Patients with High-Grade Pancreatic Neuroendocrine Carcinoma: A Nordic Multicenter Comparative Study. Ann Surg Oncol 2016;23:1721-8. [PMID: 26678407 DOI: 10.1245/s10434-015-5013-2] [Cited by in Crossref: 40] [Cited by in F6Publishing: 37] [Article Influence: 6.7] [Reference Citation Analysis]
67 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
68 Lebwohl D, Anak Ö, Sahmoud T, Klimovsky J, Elmroth I, Haas T, Posluszny J, Saletan S, Berg W. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases: Development of everolimus, an oral mTOR inhibitor. Ann N Y Acad Sci 2013;1291:14-32. [DOI: 10.1111/nyas.12122] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.9] [Reference Citation Analysis]
69 Rehfeld A, Plass M, Døssing K, Knigge U, Kjær A, Krogh A, Friis-Hansen L. Alternative polyadenylation of tumor suppressor genes in small intestinal neuroendocrine tumors. Front Endocrinol (Lausanne) 2014;5:46. [PMID: 24782827 DOI: 10.3389/fendo.2014.00046] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
70 Watson C, Tallentire CW, Ramage JK, Srirajaskanthan R, Leeuwenkamp OR, Fountain D. Quality of life in patients with gastroenteropancreatic tumours: A systematic literature review. World J Gastroenterol 2020; 26(25): 3686-3711 [PMID: 32742136 DOI: 10.3748/wjg.v26.i25.3686] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
71 Norton JA, Foster DS, Ito T, Jensen RT. Gastrinomas: Medical or Surgical Treatment. Endocrinol Metab Clin North Am. 2018;47:577-601. [PMID: 30098717 DOI: 10.1016/j.ecl.2018.04.009] [Cited by in Crossref: 20] [Cited by in F6Publishing: 15] [Article Influence: 10.0] [Reference Citation Analysis]
72 Berner AM, Pipinikas C, Ryan A, Dibra H, Moghul I, Webster A, Luong TV, Thirlwell C. Diagnostic Approaches to Neuroendocrine Neoplasms of Unknown Primary Site. Neuroendocrinology 2020;110:563-73. [PMID: 31658461 DOI: 10.1159/000504370] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
73 Caplin M. The recent European approval of lutetium ( 177 Lu) oxodotreotide increases treatment options for gastroenteropancreatic neuroendocrine tumors. International Journal of Endocrine Oncology 2018;5:IJE09. [DOI: 10.2217/ije-2018-0002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
74 Gorelik M, Ahmad M, Grossman D, Grossman M, Cooperman AM. Nonfunctioning Incidental Pancreatic Neuroendocrine Tumors. Surgical Clinics of North America 2018;98:157-67. [DOI: 10.1016/j.suc.2017.09.014] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
75 Dilz LM, Denecke T, Steffen IG, Prasad V, von Weikersthal LF, Pape UF, Wiedenmann B, Pavel M. Streptozocin/5-fluorouracil chemotherapy is associated with durable response in patients with advanced pancreatic neuroendocrine tumours. Eur J Cancer. 2015;51:1253-1262. [PMID: 25935542 DOI: 10.1016/j.ejca.2015.04.005] [Cited by in Crossref: 52] [Cited by in F6Publishing: 45] [Article Influence: 8.7] [Reference Citation Analysis]
76 Sorbye H, Baudin E, Perren A. The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond. Endocrinol Metab Clin North Am. 2018;47:683-698. [PMID: 30098724 DOI: 10.1016/j.ecl.2018.05.001] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 9.7] [Reference Citation Analysis]
77 Köseoğlu H, Duzenli T, Sezikli M. Gastric neuroendocrine neoplasms: A review. World J Clin Cases 2021; 9(27): 7973-7985 [PMID: 34621854 DOI: 10.12998/wjcc.v9.i27.7973] [Reference Citation Analysis]
78 Harimoto N, Araki K, Hoshino K, Muranushi R, Hagiwara K, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Kubo N, Tomonaga H, Higuchi T, Tsushima Y, Ikota H, Shirabe K. Diffusion-Weighted MRI Predicts Lymph Node Metastasis and Tumor Aggressiveness in Resectable Pancreatic Neuroendocrine Tumors. World J Surg 2020;44:4136-41. [PMID: 32797282 DOI: 10.1007/s00268-020-05736-3] [Reference Citation Analysis]
79 Robbins HL, Hague A. The PI3K/Akt Pathway in Tumors of Endocrine Tissues. Front Endocrinol (Lausanne) 2015;6:188. [PMID: 26793165 DOI: 10.3389/fendo.2015.00188] [Cited by in Crossref: 38] [Cited by in F6Publishing: 49] [Article Influence: 7.6] [Reference Citation Analysis]
80 Briest F, Grabowski P. The p53 network as therapeutic target in gastroenteropancreatic neuroendocrine neoplasms. Cancer Treat Rev 2015;41:423-30. [PMID: 25837868 DOI: 10.1016/j.ctrv.2015.03.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
81 Bodei L, Kidd M, Modlin IM, Prasad V, Severi S, Ambrosini V, Kwekkeboom DJ, Krenning EP, Baum RP, Paganelli G, Drozdov I. Gene transcript analysis blood values correlate with 68Ga-DOTA-somatostatin analog (SSA) PET/CT imaging in neuroendocrine tumors and can define disease status. Eur J Nucl Med Mol Imaging 2015;42:1341-52. [DOI: 10.1007/s00259-015-3075-9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 26] [Article Influence: 4.2] [Reference Citation Analysis]
82 Büyükaşık K, Arı A, Tatar C, Akçe B, Sevinç MM, Sarı S, Paşaoğlu E, Bektaş H. Clinicopathological features of gastroenteropancreatic neuroendocrine tumors: A retrospective evaluation of 42 cases. Turk J Surg 2017;33:279-83. [PMID: 29260133 DOI: 10.5152/UCD.2017.3685] [Reference Citation Analysis]
83 Lesén E, Granfeldt D, Berthon A, Dinet J, Houchard A, Myrenfors P, Björstad Å, Björholt I, Elf AK, Johanson V. Treatment Patterns and Survival among Patients with Metastatic Gastroenteropancreatic Neuroendocrine Tumours in Sweden - a Population-based Register-linkage and Medical Chart Review Study. J Cancer 2019;10:6876-87. [PMID: 31839822 DOI: 10.7150/jca.32381] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
84 Rindi G, Petrone G, Inzani F. The 2010 WHO classification of digestive neuroendocrine neoplasms: a critical appraisal four years after its introduction. Endocr Pathol. 2014;25:186-192. [PMID: 24699927 DOI: 10.1007/s12022-014-9313-z] [Cited by in Crossref: 100] [Cited by in F6Publishing: 89] [Article Influence: 16.7] [Reference Citation Analysis]
85 Wong KP, Tsang JS, Lang BH. Role of surgery in pancreatic neuroendocrine tumor. Gland Surg 2018;7:36-41. [PMID: 29629318 DOI: 10.21037/gs.2017.12.05] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
86 Min LA, Castagnoli F, Vogel WV, Vellenga JP, van Griethuysen JJM, Lahaye MJ, Maas M, Beets Tan RGH, Lambregts DMJ. A decade of multi-modality PET and MR imaging in abdominal oncology. Br J Radiol 2021;:20201351. [PMID: 34387508 DOI: 10.1259/bjr.20201351] [Reference Citation Analysis]
87 Chen S, Chang Y, Hwang T, Chen J, Chou W, Hsieh C, Yeh T, Hsu J, Yeh C, Tseng J, Chen T, Yen T. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan. Journal of the Formosan Medical Association 2018;117:480-7. [DOI: 10.1016/j.jfma.2017.07.007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
88 Sherman SK, Maxwell JE, O'Dorisio MS, O'Dorisio TM, Howe JR. Pancreastatin predicts survival in neuroendocrine tumors. Ann Surg Oncol 2014;21:2971-80. [PMID: 24752611 DOI: 10.1245/s10434-014-3728-0] [Cited by in Crossref: 38] [Cited by in F6Publishing: 33] [Article Influence: 5.4] [Reference Citation Analysis]
89 Tamagno G, Scherer V, Caimo A, Bergmann SR, Kann PH. Endoscopic Ultrasound Features of Multiple Endocrine Neoplasia Type 1-Related versus Sporadic Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Study. Digestion. 2018;98:112-118. [PMID: 29698969 DOI: 10.1159/000487939] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.3] [Reference Citation Analysis]
90 Katalinic D, Santek F, Juretic A, Skegro D, Plestina S. Gastroenteropancreatic neuroendocrine tumour arising in Meckel's diverticulum coexisting with colon adenocarcinoma. World J Surg Oncol 2014;12:358. [PMID: 25427657 DOI: 10.1186/1477-7819-12-358] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
91 Zhang L, Yang Z, Chen Q, Li M, Zhu X, Wan D, Xie H, Zheng S. Mixed adenoendocrine carcinoma in the extrahepatic biliary tract: A case report and literature review. Oncol Lett 2019;18:1585-96. [PMID: 31423226 DOI: 10.3892/ol.2019.10502] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
92 Raspanti C, Falco N, Silvestri V, Rotolo G, Bonventre S, Gulotta G. Neuroendocrine tumor of the common bile duct: case report. G Chir 2016;37:275-80. [PMID: 28350976 DOI: 10.11138/gchir/2016.37.6.275] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
93 Dumars C, Foubert F, Touchefeu Y, Regenet N, Senellart H, Matysiak-budnik T, Heymann M. Can PPH3 be helpful to assess the discordant grade in primary and metastatic enteropancreatic neuroendocrine tumors? Endocrine 2016;53:395-401. [DOI: 10.1007/s12020-016-0944-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
94 Berardi R, Rinaldi S, Torniai M, Morgese F, Partelli S, Caramanti M, Onofri A, Polenta V, Pagliaretta S, Falconi M, Cascinu S. Gastrointestinal neuroendocrine tumors: Searching the optimal treatment strategy—A literature review. Critical Reviews in Oncology/Hematology 2016;98:264-74. [DOI: 10.1016/j.critrevonc.2015.11.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
95 Tsoukalas N, Galanopoulos M, Tolia M, Kiakou M, Nakos G, Papakostidi A, Koumakis G. Rectal neuroendocrine tumor with uncommon metastatic spread: A case report and review of literature. World J Gastrointest Oncol 2016; 8(2): 231-234 [PMID: 26909138 DOI: 10.4251/wjgo.v8.i2.231] [Reference Citation Analysis]
96 Panzuto F, Cicchese N, Partelli S, Rinzivillo M, Capurso G, Merola E, Manzoni M, Pucci E, Iannicelli E, Pilozzi E, Rossi M, Doglioni C, Falconi M, Delle Fave G. Impact of Ki67 re-assessment at time of disease progression in patients with pancreatic neuroendocrine neoplasms. PLoS One. 2017;12:e0179445. [PMID: 28644861 DOI: 10.1371/journal.pone.0179445] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
97 Vinik AI, Wolin EM, Liyanage N, Gomez-Panzani E, Fisher GA, ELECT Study Group *. Evaluation of lanreotide depot/autogel efficacy and safety as a carcinoid syndrome treatment (ELECT): a randomized, double-blind, placebo-controlled trial. Endocr Pract. 2016;22:1068-1080. [PMID: 27214300 DOI: 10.4158/ep151172.or] [Cited by in Crossref: 44] [Cited by in F6Publishing: 32] [Article Influence: 8.8] [Reference Citation Analysis]
98 Scharf M, Mueller D, Koenig U, Pfestroff A, Nimphius W, Figiel J, Rinke A, Koenig A, Gress T. Management of a metastasized high grade insulinoma (G3) with refractory hypoglycemia: Case report and review of the literature. Pancreatology 2014;14:542-5. [DOI: 10.1016/j.pan.2014.07.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
99 Cives M, Soares HP, Strosberg J. Will clinical heterogeneity of neuroendocrine tumors impact their management in the future? Lessons from recent trials. Curr Opin Oncol 2016;28:359-66. [PMID: 27138571 DOI: 10.1097/CCO.0000000000000299] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 4.8] [Reference Citation Analysis]
100 Fernandes D, Soares JB, Rolanda C. Gastric Mixed Adenoneuroendocrine Carcinoma. GE Port J Gastroenterol 2015;22:34-6. [PMID: 28868368 DOI: 10.1016/j.jpge.2014.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
101 Sclafani F, Hesselberg G, Thompson SR, Truskett P, Haghighi K, Rao S, Goldstein D. Multimodality treatment of oligometastatic anal squamous cell carcinoma: A case series and literature review: SCLAFANI et al.. J Surg Oncol 2019;119:489-96. [DOI: 10.1002/jso.25320] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
102 Pusceddu S, Barretta F, Trama A, Botta L, Milione M, Buzzoni R, De Braud F, Mazzaferro V, Pastorino U, Seregni E, Mariani L, Gatta G, Di Bartolomeo M, Femia D, Prinzi N, Coppa J, Panzuto F, Antonuzzo L, Bajetta E, Brizzi MP, Campana D, Catena L, Comber H, Dwane F, Fazio N, Faggiano A, Giuffrida D, Henau K, Ibrahim T, Marconcini R, Massironi S, Žakelj MP, Spada F, Tafuto S, Van Eycken E, Van der Zwan JM, Žagar T, Giacomelli L, Miceli R; NEPscore Working Group. A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. Endocr Relat Cancer 2018;25:607-18. [PMID: 29559553 DOI: 10.1530/ERC-17-0489] [Cited by in Crossref: 10] [Cited by in F6Publishing: 3] [Article Influence: 3.3] [Reference Citation Analysis]
103 Lee L, Ito T, Jensen RT. Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence. Expert Opin Pharmacother 2018;19:909-28. [PMID: 29757017 DOI: 10.1080/14656566.2018.1476492] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
104 Sherman SK, Maxwell JE, Carr JC, Wang D, Bellizzi AM, Sue O'Dorisio M, O'Dorisio TM, Howe JR. Gene expression accurately distinguishes liver metastases of small bowel and pancreas neuroendocrine tumors. Clin Exp Metastasis 2014;31:935-44. [PMID: 25241033 DOI: 10.1007/s10585-014-9681-2] [Cited by in Crossref: 17] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
105 Öberg K, Lamberts SW. Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future. Endocr Relat Cancer 2016;23:R551-66. [PMID: 27697899 DOI: 10.1530/ERC-16-0151] [Cited by in Crossref: 44] [Cited by in F6Publishing: 25] [Article Influence: 8.8] [Reference Citation Analysis]
106 Khan TM, Garg M, Warner RR, Uhr JH, Divino CM. Elevated Serum Pancreastatin Is an Indicator of Hepatic Metastasis in Patients With Small Bowel Neuroendocrine Tumors. Pancreas 2016;45:1032-5. [PMID: 26684860 DOI: 10.1097/MPA.0000000000000572] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 1.8] [Reference Citation Analysis]
107 Ranade R, Basu S. 177 Lu-DOTATATE PRRT in Patients with Metastatic Neuroendocrine Tumor and a Single Functioning Kidney: Tolerability and Effect on Renal Function. J Nucl Med Technol 2016;44:65-9. [DOI: 10.2967/jnmt.115.168146] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
108 Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers 2019;11:828. [DOI: 10.3390/cancers11060828] [Reference Citation Analysis]
109 McKenna LR, Edil BH. Update on pancreatic neuroendocrine tumors. Gland Surg. 2014;3:258-275. [PMID: 25493258 DOI: 10.3978/j.issn.2227-684x.2014.06.03] [Cited by in F6Publishing: 23] [Reference Citation Analysis]
110 Has Simsek D, Kuyumcu S, Turkmen C, Sanlı Y, Aykan F, Unal S, Adalet I. Can complementary 68Ga-DOTATATE and 18F-FDG PET/CT establish the missing link between histopathology and therapeutic approach in gastroenteropancreatic neuroendocrine tumors? J Nucl Med 2014;55:1811-7. [PMID: 25315243 DOI: 10.2967/jnumed.114.142224] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 6.9] [Reference Citation Analysis]
111 Gulpinar B, Peker E, Soydal C, Araz M, Elhan AH. Can we differentiate histologic subtypes of neuroendocrine tumour liver metastases at a single phase contrast-enhanced CT-correlation with Ga-68 DOTATATE PET/CT findings. Br J Radiol 2020;93:20190735. [PMID: 31922897 DOI: 10.1259/bjr.20190735] [Reference Citation Analysis]
112 Bolzacchini E, Chini C, Cortelezzi CC, Vallini I, Pinotti G, La Rosa S, Uccella S. Poorly Differentiated Neuroendocrine Carcinoma of the Sigmoid Tract in Long-Standing Ulcerative Colitis: Report of a Case and Review of the Literature. Int J Surg Pathol 2018;26:479-83. [DOI: 10.1177/1066896917752443] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
113 Flaum N, Valle JW, Mansoor W, Mcnamara MG. Everolimus in the treatment of neuroendocrine tumors of the respiratory and gastroenteropancreatic systems. Future Oncology 2016;12:2561-78. [DOI: 10.2217/fon.16.23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
114 Basu S, Parghane R, Ranade R, Thapa P, Ramaswamy A, Ostwal V, Sirohi B, Panda D, Shrikhande SV. Peptide Receptor Radionuclide Therapy in the Management of Neuroendocrine Tumors (Neoplasms): Fundamentals and Salient Clinical Practice Points for Medical Oncologists. Indian Journal of Medical and Paediatric Oncology 2021;40:165-71. [DOI: 10.4103/ijmpo.ijmpo_161_19] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
115 Pokuri VK, Fong MK, Iyer R. Octreotide and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2016;18:7. [PMID: 26743514 DOI: 10.1007/s11912-015-0492-7] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
116 Mantzoros I, Savvala NA, Ioannidis O, Parpoudi S, Loutzidou L, Kyriakidou D, Cheva A, Intzos V, Tsalis K. Midgut neuroendocrine tumor presenting with acute intestinal ischemia. World J Gastroenterol 2017; 23(45): 8090-8096 [PMID: 29259385 DOI: 10.3748/wjg.v23.i45.8090] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
117 Jakoby J, Beuschlein F, Mentz S, Hantel C, Süss R. Liposomal doxorubicin for active targeting: surface modification of the nanocarrier evaluated in vitro and in vivo: challenges and prospects. Oncotarget 2015;6:43698-711. [PMID: 26497207 DOI: 10.18632/oncotarget.6191] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
118 Zou J, Chen S, Lian G, Li R, Li Y, Huang K, Chen Y. Prognostic and metastasis-related factors in colorectal neuroendocrine tumors: A cross-sectional study based on the Surveillance, Epidemiology and End Results. Oncol Lett 2019;18:5129-38. [PMID: 31612024 DOI: 10.3892/ol.2019.10876] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
119 Lin Z, Wang H, Zhang Y, Li G, Pi G, Yu X, Chen Y, Jin K, Chen L, Yang S, Zhu Y, Wu G, Chen J, Zhang T. Development and Validation of a Prognostic Nomogram to Guide Decision-Making for High-Grade Digestive Neuroendocrine Neoplasms. Oncologist 2020;25:e659-67. [PMID: 32297441 DOI: 10.1634/theoncologist.2019-0566] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
120 Hong L, Wang Y, Zhang T, Zhang C, Wang L, Wang L, Wang Z, Zhong J. Chromogranin A: A Valuable Serum Diagnostic Marker for Non-Insulinoma Neuroendocrine Tumors of the Pancreas in a Chinese Population. Med Sci Monit 2020;26:e926635. [PMID: 33141811 DOI: 10.12659/MSM.926635] [Reference Citation Analysis]
121 Sartori S, Tombesi P, Di Vece F, Bianchi L, Ambrosio R. Percutaneous Laser Ablation of Liver Metastases from Neuroendocrine Neoplasm. A Retrospective Study for Safety and Effectiveness. Cardiovasc Intervent Radiol. 2019;42:1571-1578. [PMID: 31410534 DOI: 10.1007/s00270-019-02308-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
122 Öberg K. Neuroendocrine gastro-enteropancreatic tumors - from eminence based to evidence-based medicine - A Scandinavian view. Scand J Gastroenterol 2015;50:727-39. [PMID: 25855088 DOI: 10.3109/00365521.2015.1033001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
123 Musholt TJ, Watzka FM. Neuroendokrine Neoplasien des gastroenteropankreatischen Systems: Chirurgische Therapie. Gastroenterologe 2015;10:410-7. [DOI: 10.1007/s11377-015-0003-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
124 Nakhaie M, Charostad J, Kaydani GA, Faghihloo E. The role of viruses in adenocarcinoma development. Infect Genet Evol 2020;86:104603. [PMID: 33091575 DOI: 10.1016/j.meegid.2020.104603] [Reference Citation Analysis]
125 de Galiza Barbosa F, Delso G, Ter Voert EE, Huellner MW, Herrmann K, Veit-Haibach P. Multi-technique hybrid imaging in PET/CT and PET/MR: what does the future hold? Clin Radiol 2016;71:660-72. [PMID: 27108800 DOI: 10.1016/j.crad.2016.03.013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
126 Akirov A, Larouche V, Alshehri S, Asa SL, Ezzat S. Treatment Options for Pancreatic Neuroendocrine Tumors. Cancers (Basel) 2019;11:E828. [PMID: 31207914 DOI: 10.3390/cancers11060828] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 9.5] [Reference Citation Analysis]
127 Yang M, Zhang Y, Zeng L, Ke NW, Tan CL, Tian BL, Xiang B, Liu XB. Survivals of patients with surgically treated and High-grade pancreatic neuroendocrine carcinomas: A comparative study between two American Joint Committee on Cancer 8th tumor-node-metastasis staging systems. Eur J Surg Oncol 2019;45:1054-60. [PMID: 30661921 DOI: 10.1016/j.ejso.2019.01.010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]
128 Qiao XW, Qiu L, Chen YJ, Meng CT, Sun Z, Bai CM, Zhao DC, Zhang TP, Zhao YP, Song YL, Wang YH, Chen J, Lu CM. Chromogranin A is a reliable serum diagnostic biomarker for pancreatic neuroendocrine tumors but not for insulinomas. BMC Endocr Disord 2014;14:64. [PMID: 25099181 DOI: 10.1186/1472-6823-14-64] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 3.9] [Reference Citation Analysis]
129 Xu SS, Xu HX, Wang WQ, Li S, Li H, Li TJ, Zhang WH, Liu L, Yu XJ. Tumor-infiltrating platelets predict postoperative recurrence and survival in resectable pancreatic neuroendocrine tumor. World J Gastroenterol 2019; 25(41): 6248-6257 [PMID: 31749595 DOI: 10.3748/wjg.v25.i41.6248] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
130 Bakogeorgos M, Kalkanis D, Katsaounis P, Ramfidis V, Speliades C, Pierrakou E, Papadopoulos S, Pantazopoulos N, Georgoulias V, Kotsakis A, Kentepozidis N. Small cell carcinoma of the stomach: A report of two cases and a review of the literature. Mol Clin Oncol 2018;9:11-6. [PMID: 29896397 DOI: 10.3892/mco.2018.1624] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
131 Gaiani F, de'Angelis N, Minelli R, Kayali S, Carra MC, de'Angelis GL. Pediatric gastroenteropancreatic neuroendocrine tumor: A case report and review of the literature. Medicine (Baltimore) 2019;98:e17154. [PMID: 31517859 DOI: 10.1097/MD.0000000000017154] [Reference Citation Analysis]
132 Gaertner F, Plum T, Kreppel B, Eppard E, Meisenheimer M, Strunk H, Bundschuh R, Sinnes J, Rösch F, Essler M. Clinical evaluation of [68Ga]Ga-DATA-TOC in comparison to [68Ga]Ga-DOTA-TOC in patients with neuroendocrine tumours. Nuclear Medicine and Biology 2019;76-77:1-9. [DOI: 10.1016/j.nucmedbio.2019.08.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
133 de Laat JM, van Leeuwaarde RS, Valk GD. The Importance of an Early and Accurate MEN1 Diagnosis. Front Endocrinol (Lausanne) 2018;9:533. [PMID: 30254610 DOI: 10.3389/fendo.2018.00533] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
134 Kunikowska J, Zemczak A, Kołodziej M, Gut P, Łoń I, Pawlak D, Mikołajczak R, Kamiński G, Ruchała M, Kos-Kudła B, Królicki L. Tandem peptide receptor radionuclide therapy using 90Y/177Lu-DOTATATE for neuroendocrine tumors efficacy and side-effects - polish multicenter experience. Eur J Nucl Med Mol Imaging 2020;47:922-33. [PMID: 31980909 DOI: 10.1007/s00259-020-04690-5] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 11.0] [Reference Citation Analysis]
135 Basu S. Should grade of tracer uptake on somatostatin receptor-targeted imaging be the major determinant and break the barrier of histopathologic criteria for determining the suitability of Peptide receptor radionuclide therapy? J Nucl Med 2013;54:2018-9. [PMID: 24071506 DOI: 10.2967/jnumed.113.127829] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
136 Kaderli RM, Spanjol M, Kollár A, Bütikofer L, Gloy V, Dumont RA, Seiler CA, Christ ER, Radojewski P, Briel M, Walter MA. Therapeutic Options for Neuroendocrine Tumors: A Systematic Review and Network Meta-analysis. JAMA Oncol 2019;5:480-9. [PMID: 30763436 DOI: 10.1001/jamaoncol.2018.6720] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 32.0] [Reference Citation Analysis]
137 Palmer J, Leeuwenkamp OR. Cost-effectiveness of lutetium (177Lu) oxodotreotide vs everolimus in gastroenteropancreatic neuroendocrine tumors in Norway and Sweden. World J Clin Cases 2020; 8(20): 4793-4806 [PMID: 33195647 DOI: 10.12998/wjcc.v8.i20.4793] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
138 Capdevila J, Casanovas O, Salazar R, Castellano D, Segura A, Fuster P, Aller J, García-Carbonero R, Jimenez-Fonseca P, Grande E, Castaño JP. Translational research in neuroendocrine tumors: pitfalls and opportunities. Oncogene 2017;36:1899-907. [PMID: 27641330 DOI: 10.1038/onc.2016.316] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 4.2] [Reference Citation Analysis]
139 Pusceddu S, Prinzi N, Raimondi A, Corti F, Buzzoni R, Di Bartolomeo M, Seregni E, Maccauro M, Coppa J, Milione M, Mazzaferro V, de Braud F. Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. Tumori 2019;105:113-20. [DOI: 10.1177/0300891618765362] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
140 Pelosi G, Papotti M, Rindi G, Scarpa A. Unraveling tumor grading and genomic landscape in lung neuroendocrine tumors. Endocr Pathol 2014;25:151-64. [PMID: 24771462 DOI: 10.1007/s12022-014-9320-0] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
141 Folkert IW, Hernandez P, Roses RE. Multidisciplinary management of nonfunctional neuroendocrine tumor of the pancreas. World J Gastroenterol 2016; 22(11): 3105-3116 [PMID: 27003988 DOI: 10.3748/wjg.v22.i11.3105] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
142 James PD, Tsolakis AV, Zhang M, Belletrutti PJ, Mohamed R, Roberts DJ, Heitman SJ. Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis. Gastrointest Endosc. 2015;81:848-856.e1. [PMID: 25805462 DOI: 10.1016/j.gie.2014.12.031] [Cited by in Crossref: 26] [Cited by in F6Publishing: 16] [Article Influence: 5.2] [Reference Citation Analysis]
143 Larghi A, Rizzatti G, Rimbaş M, Crino SF, Gasbarrini A, Costamagna G. EUS-guided radiofrequency ablation as an alternative to surgery for pancreatic neuroendocrine neoplasms: Who should we treat? Endosc Ultrasound 2019;8:220-6. [PMID: 31249164 DOI: 10.4103/eus.eus_28_19] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
144 Pusceddu S, Buzzoni R, De Braud F. Pancreatic well-differentiated neuroendocrine neoplasms (pWDNENs): what place for everolimus and sunitinib derived from ESMO clinical practice guidelines in the therapeutic algorithm? Annals of Oncology 2013;24:1415-6. [DOI: 10.1093/annonc/mdt102] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
145 Galleberg R, Knigge U, Tiensuu Janson E, Vestermark L, Haugvik S, Ladekarl M, Langer S, Grønbæk H, Österlund P, Hjortland G, Assmus J, Tang L, Perren A, Sorbye H. Results after surgical treatment of liver metastases in patients with high-grade gastroenteropancreatic neuroendocrine carcinomas. European Journal of Surgical Oncology 2017;43:1682-9. [DOI: 10.1016/j.ejso.2017.04.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 4.8] [Reference Citation Analysis]
146 Basu S, Sirohi B, Shrikhande SV. Dual tracer imaging approach in assessing tumor biology and heterogeneity in neuroendocrine tumors: its correlation with tumor proliferation index and possible multifaceted implications for personalized clinical management decisions, with focus on PRRT. Eur J Nucl Med Mol Imaging 2014;41:1492-6. [PMID: 24863431 DOI: 10.1007/s00259-014-2805-8] [Cited by in Crossref: 20] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
147 Gao J, Zhang W, Ehrhardt A. Expanding the Spectrum of Adenoviral Vectors for Cancer Therapy. Cancers (Basel) 2020;12:E1139. [PMID: 32370135 DOI: 10.3390/cancers12051139] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 14.0] [Reference Citation Analysis]
148 Kelgiorgi D, Dervenis C. Pancreatic neuroendocrine tumors: the basics, the gray zone, and the target. F1000Res 2017;6:663. [PMID: 28529726 DOI: 10.12688/f1000research.10188.1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
149 Kaewput C, Suppiah S, Vinjamuri S. Correlation between Standardized Uptake Value of 68Ga-DOTA-NOC Positron Emission Tomography/Computed Tomography and Pathological Classification of Neuroendocrine Tumors. World J Nucl Med 2018;17:34-40. [PMID: 29398963 DOI: 10.4103/wjnm.WJNM_16_17] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
150 Bollard J, Patte C, Radkova K, Massoma P, Chardon L, Valantin J, Gadot N, Goddard I, Vercherat C, Hervieu V, Gouysse G, Poncet G, Scoazec JY, Walter T, Roche C. Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors. J Pathol 2019;249:343-55. [PMID: 31257576 DOI: 10.1002/path.5321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
151 Joish VN, Frech F, Lapuerta P. Budgetary Impact of Telotristat Ethyl, a Novel Treatment for Patients with Carcinoid Syndrome Diarrhea: A US Health Plan Perspective. Clin Ther 2017;39:2338-44. [PMID: 29175096 DOI: 10.1016/j.clinthera.2017.10.019] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
152 Latteyer S, Tiedje V, Schilling B, Führer D. Perspectives for immunotherapy in endocrine cancer. Endocrine-Related Cancer 2016;23:R469-84. [DOI: 10.1530/erc-16-0169] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 2.2] [Reference Citation Analysis]
153 Ulrich JD, Specht K, Schlitter AM, Ceyhan GO, Quante M, Schmid RM, Schlag C. A rare case of perivascular epithelioid cell tumor (PEComa) of the pancreas diagnosed by endoscopic ultrasound. Endosc Int Open 2020;8:E25-8. [PMID: 31921981 DOI: 10.1055/a-1038-3852] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
154 Wu Y, Gao L, Guo X, Wang Z, Lian W, Deng K, Lu L, Xing B, Zhu H. Pituitary adenomas in patients with multiple endocrine neoplasia type 1: a single-center experience in China. Pituitary 2019;22:113-23. [PMID: 30637623 DOI: 10.1007/s11102-019-00939-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
155 Minn H, Kemppainen J, Kauhanen S, Forsback S, Seppänen M. 18F-fluorodihydroxyphenylalanine in the diagnosis of neuroendocrine tumors. PET Clin 2014;9:27-36. [PMID: 25029931 DOI: 10.1016/j.cpet.2013.08.013] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
156 Gallo M, Ruggeri RM, Muscogiuri G, Pizza G, Faggiano A, Colao A; NIKE Group. Diabetes and pancreatic neuroendocrine tumours: Which interplays, if any? Cancer Treat Rev 2018;67:1-9. [PMID: 29746922 DOI: 10.1016/j.ctrv.2018.04.013] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 5.0] [Reference Citation Analysis]
157 Krug S, Boch M, Nimphius W, Gress T, Michl P, Rinke A. Relevance of dihydropyrimidine-dehydrogenase and thymidylate-synthase in patients with pancreatic neuroendocrine neoplasms treated with 5-FU-based chemotherapy. Pancreatology 2017;17:139-45. [DOI: 10.1016/j.pan.2016.12.006] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
158 Moschovis D, Gazouli M, Tzouvala M, Vezakis A, Karamanolis G. Long non-coding RNA in pancreatic adenocarcinoma and pancreatic neuroendocrine tumors. Ann Gastroenterol 2017;30:622-8. [PMID: 29118556 DOI: 10.20524/aog.2017.0185] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
159 Faggiano A, Di Maio S, Mocerino C, Ottaviano M, De Divitiis C, Guarnotta V, Dolce P, Modica R, Puliafito I, Tozzi L, Di Sarno A, Leo S, Riccardi F, Palmieri G, Tafuto S, Bianco A, Badalamenti G, Colao A; on behalf of ELIOS. Therapeutic sequences in patients with grade 1−2 neuroendocrine tumors (NET): an observational multicenter study from the ELIOS group. Endocrine 2019;66:417-24. [DOI: 10.1007/s12020-019-01894-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
160 Hou X, Birkenfeld B, Piwowarska-Bilska H, Celler A. Patient-specific dosimetry of 99mTc-HYNIC-Tyr3-Octreotide in children. EJNMMI Phys 2017;4:24. [PMID: 29030760 DOI: 10.1186/s40658-017-0191-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
161 Gao L, Natov NS, Daly KP, Masud F, Chaudhry S, Sterling MJ, Saif MW. An update on the management of pancreatic neuroendocrine tumors. Anticancer Drugs. 2018;29:597-612. [PMID: 29782352 DOI: 10.1097/cad.0000000000000633] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
162 Kalshetty A, Ramaswamy A, Ostwal V, Basu S. Resistant functioning and/or progressive symptomatic metastatic gastroenteropancreatic neuroendocrine tumors: efficacy of 177Lu-DOTATATE peptide receptor radionuclide therapy in this setting. Nuclear Medicine Communications 2018;39:1143-9. [DOI: 10.1097/mnm.0000000000000926] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
163 Carmona-Bayonas A, Jiménez-Fonseca P, Custodio A, Grande E, Capdevila J, López C, Teule A, Garcia-Carbonero R; Spanish Neuroendocrine Tumor Group (GETNE). Optimizing Somatostatin Analog Use in Well or Moderately Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Curr Oncol Rep 2017;19:72. [PMID: 28920153 DOI: 10.1007/s11912-017-0633-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
164 Carvão J, Dinis-Ribeiro M, Pimentel-Nunes P, Libânio D. Neuroendocrine Tumors of the Gastrointestinal Tract: A Focused Review and Practical Approach for Gastroenterologists. GE Port J Gastroenterol 2021;28:336-48. [PMID: 34604465 DOI: 10.1159/000512089] [Reference Citation Analysis]
165 Yao JC, Lagunes DR, Kulke MH. Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist 2013;18:525-32. [PMID: 23615698 DOI: 10.1634/theoncologist.2012-0434] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
166 Custodio A, Jimenez-Fonseca P, Carmona-Bayonas A, Gomez MJ, Del Olmo-García MI, Lorenzo I, Díaz JÁ, Canal N, De la Cruz G, Villabona C. Use of healthcare REsources and associated COsts in controlled versus uncontrolled carcinoid SYndrome in patients with neuroendocrine tumours: the RECOSY study. Clin Transl Oncol 2021;23:2046-56. [PMID: 34109562 DOI: 10.1007/s12094-021-02608-7] [Reference Citation Analysis]
167 Mapelli P, Aboagye EO, Stebbing J, Sharma R. Epigenetic changes in gastroenteropancreatic neuroendocrine tumours. Oncogene 2015;34:4439-47. [DOI: 10.1038/onc.2014.379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
168 Conte B, George B, Overman M, Estrella J, Jiang ZQ, Mehrvarz Sarshekeh A, Ferrarotto R, Hoff PM, Rashid A, Yao JC, Kopetz S, Dasari A. High-Grade Neuroendocrine Colorectal Carcinomas: A Retrospective Study of 100 Patients. Clin Colorectal Cancer. 2016;15:e1-e7. [PMID: 26810202 DOI: 10.1016/j.clcc.2015.12.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
169 Hatanaka T, Naganuma A, Saito T, Hoshino T, Kakizaki S, Kumasaka T, Takamoto T, Makuuchi M. Intratumoral Hemorrhage of Liver Metastasis from a Rectal Neuroendocrine Tumor. Intern Med 2019;58:217-23. [PMID: 30210114 DOI: 10.2169/internalmedicine.1140-18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
170 Wanek J, Gaisberger M, Beyreis M, Mayr C, Helm K, Primavesi F, Jäger T, Di Fazio P, Jakab M, Wagner A, Neureiter D, Kiesslich T. Pharmacological Inhibition of Class IIA HDACs by LMK-235 in Pancreatic Neuroendocrine Tumor Cells. Int J Mol Sci 2018;19:E3128. [PMID: 30321986 DOI: 10.3390/ijms19103128] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
171 Sartori S, Bianchi L, Di Vece F, Tombesi P. Liver-directed therapies for liver metastases from neuroendocrine neoplasms: Can laser ablation play any role? World J Gastroenterol 2020; 26(23): 3118-3125 [PMID: 32684730 DOI: 10.3748/wjg.v26.i23.3118] [Reference Citation Analysis]
172 Guadagno E, Luglio G, Iacobelli A, Borrelli G, Castaldi A, De Rosa G, Del Basso De Caro M. A Case of Gastric Neuroendocrine Neoplasm with Mixed Grade: a Distinct Type of "High"-grade Well-Differentiated Neuroendocrine Neoplasm. Endocr Pathol 2018;29:289-93. [PMID: 29675587 DOI: 10.1007/s12022-018-9528-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
173 Nilica B, Waitz D, Stevanovic V, Uprimny C, Kendler D, Buxbaum S, Warwitz B, Gerardo L, Henninger B, Virgolini I, Rodrigues M. Direct comparison of (68)Ga-DOTA-TOC and (18)F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. Eur J Nucl Med Mol Imaging 2016;43:1585-92. [PMID: 26922350 DOI: 10.1007/s00259-016-3328-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 7.4] [Reference Citation Analysis]
174 Bar-Moshe Y, Mazeh H, Grozinsky-Glasberg S. Non-functioning pancreatic neuroendocrine tumors: Surgery or observation? World J Gastrointest Endosc 2017; 9(4): 153-161 [PMID: 28465781 DOI: 10.4253/wjge.v9.i4.153] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
175 Frilling A, Modlin IM, Kidd M, Russell C, Breitenstein S, Salem R, Kwekkeboom D, Lau WY, Klersy C, Vilgrain V, Davidson B, Siegler M, Caplin M, Solcia E, Schilsky R;  Working Group on Neuroendocrine Liver Metastases. Recommendations for management of patients with neuroendocrine liver metastases. Lancet Oncol. 2014;15:e8-21. [PMID: 24384494 DOI: 10.1016/s1470-2045(13)70362-0] [Cited by in Crossref: 256] [Cited by in F6Publishing: 107] [Article Influence: 36.6] [Reference Citation Analysis]
176 Xu JM, Wang Y, Chen YL, Jia R, Li J, Gong JF, Li J, Qi C, Hua Y, Tan CR, Wang J, Li K, Sai Y, Zhou F, Ren YX, Qing WG, Jia H, Su WG, Shen L. Sulfatinib, a novel kinase inhibitor, in patients with advanced solid tumors: results from a phase I study. Oncotarget 2017;8:42076-86. [PMID: 28159938 DOI: 10.18632/oncotarget.14942] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 6.0] [Reference Citation Analysis]
177 Ergül N, Çermik TF, Dursun N. Is it possible NET-redifferentiation after chemotherapy? 68Ga DOTA-peptide imaging as a game-changer in therapy management. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2020;39:31-4. [PMID: 31122816 DOI: 10.1016/j.remn.2018.10.002] [Reference Citation Analysis]
178 Li Z, Du S, Feng W, Zhang W, Li G, Wei J, Zhang G, Zhao L. Competing risks and cause-specific mortality in patients with pancreatic neuroendocrine tumors. Eur J Gastroenterol Hepatol 2019;31:749-55. [PMID: 30601340 DOI: 10.1097/MEG.0000000000001350] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
179 Zou J, Li Q, Kou F, Zhu Y, Lu M, Li J, Lu Z, Shen L. Prognostic value of inflammation-based markers in advanced or metastatic neuroendocrine tumours. Curr Oncol. 2019;26:e30-e38. [PMID: 30853807 DOI: 10.3747/co.26.4135] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
180 Santos AP, Santos AC, Castro C, Raposo L, Pereira SS, Torres I, Henrique R, Cardoso H, Monteiro MP. Visceral Obesity and Metabolic Syndrome Are Associated with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel) 2018;10:E293. [PMID: 30150555 DOI: 10.3390/cancers10090293] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
181 Sorbye H, Meyer LS, Mordal KE, Myhre S, Thiis-Evensen E. Patient reported symptoms, coping and quality of life during somatostatin analogue treatment for metastatic small- intestinal neuroendocrine tumours. Health Qual Life Outcomes 2020;18:188. [PMID: 32546236 DOI: 10.1186/s12955-020-01452-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Basu S, Ranade R, Thapa P. Metastatic Neuroendocrine Tumor with Extensive Bone Marrow Involvement at Diagnosis: Evaluation of Response and Hematological Toxicity Profile of PRRT with (177)Lu-DOTATATE. World J Nucl Med 2016;15:38-43. [PMID: 26912977 DOI: 10.4103/1450-1147.165353] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 0.2] [Reference Citation Analysis]
183 Chiramel J, Almond R, Slagter A, Khan A, Wang X, Lim KHJ, Frizziero M, Chakrabarty B, Minicozzi A, Lamarca A, Mansoor W, Hubner RA, Valle JW, McNamara MG. Prognostic importance of lymph node yield after curative resection of gastroenteropancreatic neuroendocrine tumours. World J Clin Oncol 2020; 11(4): 205-216 [PMID: 32355642 DOI: 10.5306/wjco.v11.i4.205] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
184 Kjaer A, Knigge U. Use of radioactive substances in diagnosis and treatment of neuroendocrine tumors. Scand J Gastroenterol. 2015;50:740-747. [PMID: 25959100 DOI: 10.3109/00365521.2015.1033454] [Cited by in Crossref: 34] [Cited by in F6Publishing: 29] [Article Influence: 6.8] [Reference Citation Analysis]
185 Heikkonen J, Mäenpää H, Hippeläinen E, Reijonen V, Tenhunen M. Effect of calculation method on kidney dosimetry in 177 Lu-octreotate treatment. Acta Oncologica 2016;55:1069-76. [DOI: 10.1080/0284186x.2016.1182642] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 3.4] [Reference Citation Analysis]
186 Orgera G, Krokidis M, Cappucci M, Gourtsoyianni S, Tipaldi MA, Hatzidakis A, Rebonato A, Rossi M. Current status of Interventional Radiology in the management of Gastro-Entero-Pancreatic Neuroendocrine Tumours (GEP-NETs). Cardiovasc Intervent Radiol. 2015;38:13-24. [PMID: 25366087 DOI: 10.1007/s00270-014-1005-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
187 Sherman SK, Carr JC, Wang D, O'Dorisio MS, O'Dorisio TM, Howe JR. Gastric inhibitory polypeptide receptor (GIPR) is a promising target for imaging and therapy in neuroendocrine tumors. Surgery 2013;154:1206-13; discussion 1214. [PMID: 24238043 DOI: 10.1016/j.surg.2013.04.052] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
188 Xavier S, Rosa B, Cotter J. Small bowel neuroendocrine tumors: From pathophysiology to clinical approach. World J Gastrointest Pathophysiol 2016; 7(1): 117-124 [PMID: 26909234 DOI: 10.4291/wjgp.v7.i1.117] [Cited by in CrossRef: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
189 Pulvirenti A, Pea A, Chang DK, Jamieson NB. Clinical and Molecular Risk Factors for Recurrence Following Radical Surgery of Well-Differentiated Pancreatic Neuroendocrine Tumors. Front Med (Lausanne) 2020;7:385. [PMID: 32850899 DOI: 10.3389/fmed.2020.00385] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
190 Joish VN, Frech F, Lapuerta P. Cost-effectiveness analysis of telotristat ethyl for treatment of carcinoid syndrome diarrhea inadequately controlled with somatostatin analogs. J Med Econ 2018;21:182-8. [PMID: 28959913 DOI: 10.1080/13696998.2017.1387120] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
191 Gock M, Mullins CS, Harnack C, Prall F, Ramer R, Göder A, Krämer OH, Klar E, Linnebacher M. Establishment, functional and genetic characterization of a colon derived large cell neuroendocrine carcinoma cell line. World J Gastroenterol 2018; 24(33): 3749-3759 [PMID: 30197480 DOI: 10.3748/wjg.v24.i33.3749] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
192 Fust K, Maschio M, Kohli M, Singh S, Pritchard DM, Marteau F, Myrenfors P, Feuilly M. A Budget Impact Model of the Addition of Telotristat Ethyl Treatment to the Standard of Care in Patients with Uncontrolled Carcinoid Syndrome. PharmacoEconomics 2020;38:607-18. [DOI: 10.1007/s40273-020-00896-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
193 Orlewska E, Bednarczuk T, Kaminski G, Kos-Kudla B; LanroNET study group*. LanroNET, a non-interventional, prospective study to assess the resource utilization and cost of lanreotide autogel 120 mg in Polish patients with neuroendocrine tumors - results of interim analysis. Contemp Oncol (Pozn) 2014;18:442-7. [PMID: 25784845 DOI: 10.5114/wo.2014.47908] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
194 Horiguchi S, Kato H, Shiraha H, Tsutsumi K, Yamamoto N, Matsumoto K, Tomoda T, Uchida D, Akimoto Y, Mizukawa S, Tanaka T, Ichimura K, Takaki A, Yagi T, Okada H. Dynamic computed tomography is useful for prediction of pathological grade in pancreatic neuroendocrine neoplasm: Dynamic computed tomography. Journal of Gastroenterology and Hepatology 2017;32:925-31. [DOI: 10.1111/jgh.13594] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
195 Ligiero Braga T, Santos-Oliveira R. PPoma Review: Epidemiology, Aetiopathogenesis, Prognosis and Treatment. Diseases 2018;6:E8. [PMID: 29324681 DOI: 10.3390/diseases6010008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
196 Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR, Bondanelli M, Colao A, Faggiano A. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame. Endocrine-Related Cancer 2018;25:R11-29. [DOI: 10.1530/erc-17-0269] [Cited by in Crossref: 49] [Cited by in F6Publishing: 27] [Article Influence: 16.3] [Reference Citation Analysis]
197 Cheung VTF, Khan MS. A guide to midgut neuroendocrine tumours (NETs) and carcinoid syndrome. Frontline Gastroenterol. 2015;6:264-269. [PMID: 28839822 DOI: 10.1136/flgastro-2014-100483] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
198 Carr JC, Sherman SK, Wang D, Dahdaleh FS, Bellizzi AM, O'Dorisio MS, O'Dorisio TM, Howe JR. Overexpression of membrane proteins in primary and metastatic gastrointestinal neuroendocrine tumors. Ann Surg Oncol 2013;20 Suppl 3:S739-46. [PMID: 24114056 DOI: 10.1245/s10434-013-3318-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
199 Sevilla I, Segura Á, Capdevila J, López C, García-Carbonero R, Grande E; GETNE (Spanish Group of NeuroEndocrine Tumors). Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program. BMC Cancer 2016;16:858. [PMID: 27821081 DOI: 10.1186/s12885-016-2901-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
200 Villa Grajeda MG, Ronquillo Carreón CA, Morán Mendoza ADJ, Dip Borunda AK. Tumores neuroendocrinos: experiencia de 6 años en un centro de tercer nivel. Gaceta Mexicana de Oncología 2015;14:141-9. [DOI: 10.1016/j.gamo.2015.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
201 Guarnotta V, Martini C, Davì MV, Pizza G, Colao A, Faggiano A; NIKE group. The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?Endocrine. 2018;60:15-27. [PMID: 29019150 DOI: 10.1007/s12020-017-1420-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
202 Bocchini M, Nicolini F, Severi S, Bongiovanni A, Ibrahim T, Simonetti G, Grassi I, Mazza M. Biomarkers for Pancreatic Neuroendocrine Neoplasms (PanNENs) Management-An Updated Review. Front Oncol 2020;10:831. [PMID: 32537434 DOI: 10.3389/fonc.2020.00831] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
203 Wang JB, Xue Z, Lu J, He QL, Zheng ZF, Xu BB, Xie JW, Li P, Xu Y, Lin JX, Chen QY, Cao LL, Lin M, Tu RH, Huang ZN, Lin JL, Huang CM, Zheng CH. Effect of sarcopenia on short- and long-term outcomes in patients with gastric neuroendocrine neoplasms after radical gastrectomy: results from a large, two-institution series. BMC Cancer 2020;20:1002. [PMID: 33059606 DOI: 10.1186/s12885-020-07506-9] [Reference Citation Analysis]
204 Herrera-Martínez AD, Feelders RA, de Herder WW, Castaño JP, Gálvez Moreno MÁ, Dogan F, van Dungen R, van Koetsveld P, Hofland LJ. Effects of Ketoconazole on ACTH-Producing and Non-ACTH-Producing Neuroendocrine Tumor Cells. Horm Cancer 2019;10:107-19. [PMID: 31102172 DOI: 10.1007/s12672-019-00361-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
205 Faure M, Niccoli P, Autret A, Cavaglione G, Mineur L, Raoul JL. Systemic chemotherapy with FOLFOX in metastatic grade 1/2 neuroendocrine cancer. Mol Clin Oncol 2017;6:44-8. [PMID: 28123727 DOI: 10.3892/mco.2016.1097] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
206 Qian SY, Hare MJL, Pham A, Topliss DJ. Insulinoma presenting with post-prandial hypoglycaemia following fundoplication. Endocrinol Diabetes Metab Case Rep 2018;2018:EDM-17-0131. [PMID: 29367876 DOI: 10.1530/EDM-17-0131] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
207 Ludwig JM, Ambinder EM, Ghodadra A, Xing M, Prajapati HJ, Kim HS. Lung Shunt Fraction prior to Yttrium-90 Radioembolization Predicts Survival in Patients with Neuroendocrine Liver Metastases: Single-Center Prospective Analysis. Cardiovasc Intervent Radiol 2016;39:1007-14. [DOI: 10.1007/s00270-016-1323-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
208 Gulpinar B, Peker E, Kul M, Elhan AH, Haliloglu N. Liver metastases of neuroendocrine tumors: is it possible to diagnose different histologic subtypes depending on multiphasic CT features? Abdom Radiol (NY) 2019;44:2147-55. [PMID: 30863999 DOI: 10.1007/s00261-019-01963-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
209 Khan M, Dirweesh A, Alvarez C, Conaway H, Moser R. Anal Neuroendocrine Tumor Masquerading as External Hemorrhoids: A Case Report. Gastroenterology Res. 2017;10:56-58. [PMID: 28270879 DOI: 10.14740/gr751w] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
210 Armbruster M, Zech CJ, Sourbron S, Ceelen F, Auernhammer CJ, Rist C, Haug A, Singnurkar A, Reiser MF, Sommer WH. Diagnostic accuracy of dynamic gadoxetic-acid-enhanced MRI and PET/CT compared in patients with liver metastases from neuroendocrine neoplasms. J Magn Reson Imaging. 2014;40:457-466. [PMID: 24347148 DOI: 10.1002/jmri.24363] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.3] [Reference Citation Analysis]
211 Zaidi MY, Lopez-Aguiar AG, Switchenko JM, Lipscomb J, Andreasi V, Partelli S, Gamboa AC, Lee RM, Poultsides GA, Dillhoff M, Rocha FG, Idrees K, Cho CS, Weber SM, Fields RC, Staley CA 3rd, Falconi M, Maithel SK. A Novel Validated Recurrence Risk Score to Guide a Pragmatic Surveillance Strategy After Resection of Pancreatic Neuroendocrine Tumors: An International Study of 1006 Patients. Ann Surg 2019;270:422-33. [PMID: 31283562 DOI: 10.1097/SLA.0000000000003461] [Cited by in Crossref: 22] [Cited by in F6Publishing: 9] [Article Influence: 22.0] [Reference Citation Analysis]
212 Allmark A, Brubaker ML. Small cell neuroendocrine carcinoma disguised as an external hemorrhoid. JAAPA 2021;34:35-9. [PMID: 34320538 DOI: 10.1097/01.JAA.0000742960.70174.8d] [Reference Citation Analysis]
213 Foubert F, Salimon M, Dumars C, Regenet N, Girot P, Venara A, Senellart H, Heymann MF, Matysiak-Budnik T, Touchefeu Y. Survival and prognostic factors analysis of 151 intestinal and pancreatic neuroendocrine tumors: a single center experience. J Gastrointest Oncol 2019;10:103-11. [PMID: 30788165 DOI: 10.21037/jgo.2018.09.13] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
214 Pusceddu S, De Braud F, Festinese F, Bregant C, Lorenzoni A, Maccauro M, Milione M, Concas L, Formisano B, Leuzzi L, Mazzaferro V, Buzzoni R. Evolution in the treatment of gastroenteropancreatic-neuroendocrine neoplasms, focus on systemic therapeutic options: a systematic review. Future Oncology 2015;11:1947-59. [DOI: 10.2217/fon.15.86] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
215 Brown E, Watkin D, Evans J, Yip V, Cuthbertson DJ. Multidisciplinary management of refractory insulinomas. Clin Endocrinol (Oxf) 2018;88:615-24. [PMID: 29205458 DOI: 10.1111/cen.13528] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 4.3] [Reference Citation Analysis]
216 Javed AA, Hasanain A, Haider A, Jones G, Javed ZN, Soares K, Burkhart RA, Cameron JL, Weiss MJ, Wolfgang CL, He J. Clinicopathological features and surgical outcomes of resected functional pancreatic neuroendocrine tumors: a single institution experience. Journal of Pancreatology 2019;2:29-34. [DOI: 10.1097/jp9.0000000000000018] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
217 Pavel M, Becerra C, Grosch K, Cheung W, Hasskarl J, Yao J. Effect of everolimus on the pharmacokinetics of octreotide long-acting repeatable in patients with advanced neuroendocrine tumors: An analysis of the randomized phase III RADIANT-2 trial. Clin Pharmacol Ther 2017;101:462-8. [DOI: 10.1002/cpt.559] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
218 Celotti A, Pulcini G, Schieppati M, Ministrini S, Berruti A, Ronconi M. An unusual case of a well-differentiated neuroendocrine tumour of the ileum with peritoneal carcinomatosis: a case report. World J Surg Oncol 2015;13:169. [PMID: 25933800 DOI: 10.1186/s12957-015-0585-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
219 Frilling A, Clift AK, Braat AJ, Alsafi A, Wasan HS, Al-nahhas A, Thomas R, Drymousis P, Habib N, Tait PN. Radioembolisation with 90Y microspheres for neuroendocrine liver metastases: an institutional case series, systematic review and meta-analysis. HPB 2019;21:773-83. [DOI: 10.1016/j.hpb.2018.12.014] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
220 Cives M, Ghayouri M, Morse B, Brelsford M, Black M, Rizzo A, Meeker A, Strosberg J. Analysis of potential response predictors to capecitabine/temozolomide in metastatic pancreatic neuroendocrine tumors. Endocrine-Related Cancer 2016;23:759-67. [DOI: 10.1530/erc-16-0147] [Cited by in Crossref: 70] [Cited by in F6Publishing: 29] [Article Influence: 14.0] [Reference Citation Analysis]
221 Bartolini I, Bencini L, Risaliti M, Ringressi MN, Moraldi L, Taddei A. Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation. Gastroenterol Res Pract 2018;2018:9647247. [PMID: 30140282 DOI: 10.1155/2018/9647247] [Cited by in Crossref: 8] [Cited by in F6Publishing: 12] [Article Influence: 2.7] [Reference Citation Analysis]
222 Moonen L, Derks JL, Hermans BCM, Bunnik IM, Hillen LM, van Suylen RJ, den Bakker MA, von der Thüsen JH, Damhuis RA, van den Broek EC, Buikhuisen WA, Dingemans AC, Speel EJM. Preoperative Biopsy Diagnosis in Pulmonary Carcinoids, a Shot in the Dark. J Thorac Oncol 2021;16:610-8. [PMID: 33333326 DOI: 10.1016/j.jtho.2020.12.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
223 Esposito I, Schlitter A, Sipos B, Klöppel G. Klassifikation und malignes Potenzial der zystischen Pankreastumoren. Pathologe 2015;36:99-114. [DOI: 10.1007/s00292-014-1971-6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 2.1] [Reference Citation Analysis]
224 Grimaldi F, Fazio N, Attanasio R, Frasoldati A, Papini E, Angelini F, Baldelli R, Berretti D, Bianchetti S, Bizzarri G, Caputo M, Castello R, Cremonini N, Crescenzi A, Davì MV, D'Elia AV, Faggiano A, Pizzolitto S, Versari A, Zini M, Rindi G, Oberg K. Italian Association of Clinical Endocrinologists (AME) position statement: a stepwise clinical approach to the diagnosis of gastroenteropancreatic neuroendocrine neoplasms. J Endocrinol Invest 2014;37:875-909. [PMID: 25038902 DOI: 10.1007/s40618-014-0119-0] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
225 Ilett EE, Langer SW, Olsen IH, Federspiel B, Kjær A, Knigge U. Neuroendocrine Carcinomas of the Gastroenteropancreatic System: A Comprehensive Review. Diagnostics (Basel) 2015;5:119-76. [PMID: 26854147 DOI: 10.3390/diagnostics5020119] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 8.3] [Reference Citation Analysis]
226 Falconi M, Eriksson B, Kaltsas G, Bartsch DK, Capdevila J, Caplin M, Kos-Kudla B, Kwekkeboom D, Rindi G, Klöppel G. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016;103:153-171. [PMID: 26742109 DOI: 10.1159/000443171] [Cited by in Crossref: 531] [Cited by in F6Publishing: 442] [Article Influence: 106.2] [Reference Citation Analysis]
227 Almond L, Hodson J, Ford S, Gourevitch D, Roberts K, Shah T, Isaac J, Desai A. Role of palliative resection of the primary tumour in advanced pancreatic and small intestinal neuroendocrine tumours: A systematic review and meta-analysis. European Journal of Surgical Oncology (EJSO) 2017;43:1808-15. [DOI: 10.1016/j.ejso.2017.05.016] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
228 Sherman SK, Howe JR. Translational research in endocrine surgery. Surg Oncol Clin N Am 2013;22:857-84. [PMID: 24012403 DOI: 10.1016/j.soc.2013.06.012] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
229 Herrera-Martínez AD, Hofland J, Hofland LJ, Brabander T, Eskens FALM, Gálvez Moreno MA, Luque RM, Castaño JP, de Herder WW, Feelders RA. Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives. Drugs 2019;79:21-42. [PMID: 30560479 DOI: 10.1007/s40265-018-1033-0] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
230 Spychalski M, Koptas W, Zelga P, Dziki A. Role of endoscopic submucosal dissection in treatment of rectal gastroenteropancreatic neuroendocrine neoplasms. Prz Gastroenterol 2017;12:17-21. [PMID: 28337231 DOI: 10.5114/pg.2016.64635] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
231 Bodei L, Kidd M, Baum RP, Modlin IM. PRRT: Defining the paradigm shift to achieve standardization and individualization. J Nucl Med 2014;55:1753-6. [PMID: 25256058 DOI: 10.2967/jnumed.114.143974] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
232 Reed NS. Neuroendocrine tumours of the gynecological tract. Current Opinion in Oncology 2016;28:412-8. [DOI: 10.1097/cco.0000000000000321] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
233 Gomes Marin JF, Nunes RF, Coutinho AM, Zaniboni EC, Costa LB, Barbosa FG, Queiroz MA, Cerri GG, Buchpiguel CA. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology. Radiographics 2020;40:1715-40. [PMID: 33001789 DOI: 10.1148/rg.2020200021] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
234 Niederle B, Selberherr A, Niederle MB. How to Manage Small Intestine (Jejunal and Ileal) Neuroendocrine Neoplasms Presenting with Liver Metastases? Curr Oncol Rep 2021;23:85. [PMID: 34018081 DOI: 10.1007/s11912-021-01074-2] [Reference Citation Analysis]
235 Binderup T, Knigge U, Johnbeck CB, Loft A, Berthelsen AK, Oturai P, Mortensen J, Federspiel B, Langer SW, Kjaer A. 18F-FDG PET is Superior to WHO Grading as a Prognostic Tool in Neuroendocrine Neoplasms and Useful in Guiding PRRT: A Prospective 10-Year Follow-up Study. J Nucl Med 2021;62:808-15. [PMID: 33067340 DOI: 10.2967/jnumed.120.244798] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
236 Dias AR, Azevedo BC, Alban LBV, Yagi OK, Ramos MFKP, Jacob CE, Barchi LC, Cecconello I, Ribeiro U, Zilberstein B. GASTRIC NEUROENDOCRINE TUMOR: REVIEW AND UPDATE. Arq Bras Cir Dig. 2017;30:150-154. [PMID: 29257854 DOI: 10.1590/0102-6720201700020016] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 7.3] [Reference Citation Analysis]
237 Bijlsma MF, Sadanandam A, Tan P, Vermeulen L. Molecular subtypes in cancers of the gastrointestinal tract. Nat Rev Gastroenterol Hepatol 2017;14:333-42. [PMID: 28400627 DOI: 10.1038/nrgastro.2017.33] [Cited by in Crossref: 60] [Cited by in F6Publishing: 52] [Article Influence: 15.0] [Reference Citation Analysis]
238 Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. Peptide receptor radionuclide therapy for advanced neuroendocrine tumors. Thorac Surg Clin 2014;24:333-49. [PMID: 25065935 DOI: 10.1016/j.thorsurg.2014.04.005] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 5.6] [Reference Citation Analysis]
239 Laing E, Kiss N, Michael M, Gough K, Krishnasamy M. Investigating Nutrition-Related Complications and Quality of Life in Patients With Gastroenteropancreatic Neuroendocrine Tumors: Protocol for a Mixed-Methods Prospective Study. JMIR Res Protoc 2018;7:e11228. [PMID: 30567691 DOI: 10.2196/11228] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
240 Sluiter NR, van der Bilt JD, Croll DMR, Vriens MR, de Hingh IHJT, Hemmer P, Aalbers AGJ, Bremers AJA, Ceelen W, D'Hoore A, Schoonmade LJ, Coupé V, Verheul H, Kazemier G, Tuynman JB; Dutch Peritoneal Oncology Group. Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Versus Surgery Without HIPEC for Goblet-Cell Carcinoids and Mixed Adenoneuroendocrine Carcinomas: Propensity Score-Matched Analysis of Centers in the Netherlands and Belgium. Clin Colorectal Cancer 2020;19:e87-99. [PMID: 32651131 DOI: 10.1016/j.clcc.2020.01.002] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
241 Ehlerding EB, Goel S, Cai W. Cancer theranostics with ⁶⁴Cu/¹⁷⁷Lu-loaded liposomes. Eur J Nucl Med Mol Imaging 2016;43:938-40. [PMID: 26743898 DOI: 10.1007/s00259-015-3299-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
242 Melosky B. Advanced typical and atypical carcinoid tumours of the lung: management recommendations. Curr Oncol 2018;25:S86-93. [PMID: 29910651 DOI: 10.3747/co.25.3808] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
243 Yoo YJ, Yang SJ, Hwang HK, Kang CM, Kim H, Lee WJ. Overestimated Oncologic Significance of Lymph Node Metastasis in G1 Nonfunctioning Neuroendocrine Tumor in the Left Side of the Pancreas. Medicine (Baltimore). 2015;94:e1404. [PMID: 26356692 DOI: 10.1097/md.0000000000001404] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
244 Ferraro S, Borille S, Panteghini M. Reference intervals for the Kryptor second-generation chromogranin A assay. Clinical Chemistry and Laboratory Medicine (CCLM) 2016;54. [DOI: 10.1515/cclm-2016-0083] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
245 Barbosa A, Gomes F, Fonseca L, Maia T, Almeida J. De novo Gastrinoma: A Case Report. GE Port J Gastroenterol 2020;27:192-6. [PMID: 32509925 DOI: 10.1159/000503073] [Reference Citation Analysis]
246 Gleason D, Miller-hammond KE, Gibbs JF. Small Bowel Cancer. In: Chu QD, Gibbs JF, Zibari GB, editors. Surgical Oncology. New York: Springer; 2015. pp. 217-34. [DOI: 10.1007/978-1-4939-1423-4_10] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
247 Monteiro de Melo Santos D, López-Tomassetti Fernández E, Sánchez Ramos M, Hernández Hernández JR. Improved survival with palliative surgery and chemotherapy for Mixed adenoneuroendocrine carcinoma of the gastroesophageal junction with liver metastases. Cir Esp (Engl Ed) 2018;96:58-61. [PMID: 28687256 DOI: 10.1016/j.ciresp.2017.03.014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
248 Kunikowska J, Królicki L. Targeted α-Emitter Therapy of Neuroendocrine Tumors. Semin Nucl Med 2020;50:171-6. [PMID: 32172802 DOI: 10.1053/j.semnuclmed.2019.11.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 8.0] [Reference Citation Analysis]
249 Fisher GA Jr, Wolin EM, Liyanage N, Pitman Lowenthal S, Mirakhur B, Pommier RF, Shaheen M, Vinik A; ELECT Study Group. Patient-Reported Symptom Control of Diarrhea and Flushing in Patients with Neuroendocrine Tumors Treated with Lanreotide Depot/Autogel: Results from a Randomized, Placebo-Controlled, Double-Blind and 32-Week Open-Label Study. Oncologist 2018;23:16-24. [PMID: 29038234 DOI: 10.1634/theoncologist.2017-0284] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
250 Lewis AR, Wang X, Magdalani L, D’Arienzo P, Bashir C, Mansoor W, Hubner R, Valle JW, McNamara MG. Health-related quality of life, anxiety, depression and impulsivity in patients with advanced gastroenteropancreatic neuroendocrine tumours. World J Gastroenterol 2018; 24(6): 671-679 [PMID: 29456406 DOI: 10.3748/wjg.v24.i6.671] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
251 Sakamoto A, Nozawa H, Sonoda H, Hinata M, Ishii H, Emoto S, Anzai H, Yokoyama Y, Murono K, Sasaki K, Kawai K, Ushiku T, Ishihara S. Rectal neuroendocrine tumor with extracapsular lymph node metastasis: a case report. Clin J Gastroenterol 2021. [PMID: 34028785 DOI: 10.1007/s12328-021-01447-x] [Reference Citation Analysis]
252 Alexandraki KI, Karapanagioti A, Karoumpalis I, Boutzios G, Kaltsas GA. Advances and Current Concepts in the Medical Management of Gastroenteropancreatic Neuroendocrine Neoplasms. Biomed Res Int 2017;2017:9856140. [PMID: 29349087 DOI: 10.1155/2017/9856140] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
253 Alonso-Gordoa T, Díez JJ, Molina J, Reguera P, Martínez-Sáez O, Grande E. An Overview on the Sequential Treatment of Pancreatic Neuroendocrine Tumors (pNETs). Rare Cancers Ther 2015;3:13-33. [PMID: 27182476 DOI: 10.1007/s40487-015-0007-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
254 Yordanova A, Mayer K, Brossart P, Gonzalez-carmona MA, Strassburg CP, Essler M, Ahmadzadehfar H. Safety of multiple repeated cycles of 177Lu-octreotate in patients with recurrent neuroendocrine tumour. Eur J Nucl Med Mol Imaging 2017;44:1207-14. [DOI: 10.1007/s00259-017-3652-1] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
255 Johnbeck CB, Knigge U, Langer SW, Loft A, Berthelsen AK, Federspiel B, Binderup T, Kjaer A. Prognostic Value of 18 F-FLT PET in Patients with Neuroendocrine Neoplasms: A Prospective Head-to-Head Comparison with 18 F-FDG PET and Ki-67 in 100 Patients. J Nucl Med 2016;57:1851-7. [DOI: 10.2967/jnumed.116.174714] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
256 Tanaka T, Yamamoto H, Imai A, Shingo H, Yoneyama T, Koie T, Hashimoto Y, Ohyama C. A case of primary renal carcinoid tumor. Case Rep Urol 2015;2015:736213. [PMID: 25685590 DOI: 10.1155/2015/736213] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
257 Liu Q, Duan J, Zheng Y, Luo J, Cai X, Tan H. Rare malignant insulinoma with multiple liver metastases derived from ectopic pancreas: 3-year follow-up and literature review. Onco Targets Ther 2018;11:1813-9. [PMID: 29662318 DOI: 10.2147/OTT.S154991] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]